rosiglitazone has been researched along with Centriacinar Emphysema in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, H; Kang, J; Yin, Y; Zheng, R | 1 |
| Han, D; Hou, G; Kang, J; Wang, QY; Yin, Y | 1 |
2 other study(ies) available for rosiglitazone and Centriacinar Emphysema
| Article | Year |
|---|---|
Rosiglitazone ameliorated airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPARγ and RXRα.
Topics: Animals; Cigarette Smoking; Disease Models, Animal; Humans; Lung; Macrophage Activation; Macrophages, Alveolar; Male; Nicotiana; Pneumonia; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Rats; Rosiglitazone; Smoke | 2021 |
Rosiglitazone attenuates the metalloprotease/anti-metalloprotease imbalance in emphysema induced by cigarette smoke: involvement of extracellular signal-regulated kinase and NFκB signaling.
Topics: Administration, Oral; Animals; Apoptosis; Cytoprotection; Disease Models, Animal; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; I-kappa B Proteins; Inhalation Exposure; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; PPAR gamma; Pulmonary Emphysema; Rats, Wistar; Rosiglitazone; Signal Transduction; Smoke; Thiazolidinediones; Tobacco Smoke Pollution | 2015 |